Single-dose gene-editing therapy offers permanent solution to high cholesterol levels
New Scientist - 14-Nov-2023Early results show promise in eliminating the need for lifelong statins
Join the club for FREE to access the whole archive and other member benefits.
Biotechnology company
Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.
Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.
Visit website: https://www.vervetx.com/
Details last updated 29-Jun-2020
Early results show promise in eliminating the need for lifelong statins
Trials underway to test the safety, but affordability and acceptance of gene therapy are major concerns
Could prevent not only the complications but the heart disease per se in the future